• Ascentage Pharma outlined six clinical-study abstracts selected for ASCO 2026, with presentations scheduled May 29 to June 2 in Chicago.
• Data will be presented in the future, including three rapid oral sessions on olverembatinib in leukemia settings plus alrizomadlin alone or with lisaftoclax in pediatric soft-tissue sarcomas.
• Company positioned the readouts as updated efficacy and safety evidence across its lead programs, signaling continued clinical progress without disclosing outcomes in this release.
• ASCO slate also includes posters on olverembatinib activity in SDH-deficient tumors plus two phase 3 trials in progress for olverembatinib in chronic-phase CML and lisaftoclax in previously treated CLL/SLL.
• Pipeline remains unapproved by FDA, leaving near-term value tied to upcoming clinical visibility and phase 3 execution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604212000PRIMZONEFULLFEED9694486) on April 22, 2026, and is solely responsible for the information contained therein.